- Home
- BSX vs FVR Comparison
BSX vs FVR Comparison
Compare BSX & FVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSX
- FVR
- Stock Information
- Founded
- BSX 1979
- FVR 2016
- Country
- BSX United States
- FVR United States
- Employees
- BSX N/A
- FVR N/A
- Industry
- BSX Medical/Dental Instruments
- FVR
- Sector
- BSX Health Care
- FVR
- Exchange
- BSX Nasdaq
- FVR NYSE
- Market Cap
- BSX 138.5B
- FVR N/A
- IPO Year
- BSX 1992
- FVR 2024
- Fundamental
- Price
- BSX $101.15
- FVR $12.47
- Analyst Decision
- BSX Strong Buy
- FVR Strong Buy
- Analyst Count
- BSX 23
- FVR 5
- Target Price
- BSX $110.26
- FVR $20.80
- AVG Volume (30 Days)
- BSX 10.6M
- FVR 202.3K
- Earning Date
- BSX 04-23-2025
- FVR 05-14-2025
- Dividend Yield
- BSX N/A
- FVR 3.46%
- EPS Growth
- BSX 15.23
- FVR N/A
- EPS
- BSX 1.37
- FVR N/A
- Revenue
- BSX $17,554,000,000.00
- FVR $59,917,000.00
- Revenue This Year
- BSX $15.77
- FVR $18.18
- Revenue Next Year
- BSX $10.33
- FVR $19.99
- P/E Ratio
- BSX $73.80
- FVR N/A
- Revenue Growth
- BSX 19.36
- FVR 24.24
- 52 Week Low
- BSX $70.97
- FVR $10.61
- 52 Week High
- BSX $107.17
- FVR $19.76
- Technical
- Relative Strength Index (RSI)
- BSX 58.48
- FVR N/A
- Support Level
- BSX $92.70
- FVR N/A
- Resistance Level
- BSX $102.37
- FVR N/A
- Average True Range (ATR)
- BSX 4.08
- FVR 0.00
- MACD
- BSX 0.75
- FVR 0.00
- Stochastic Oscillator
- BSX 92.53
- FVR 0.00
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.